- Previous Close
18.18 - Open
18.09 - Bid 18.13 x 200
- Ask 19.78 x 200
- Day's Range
17.86 - 19.42 - 52 Week Range
12.30 - 32.81 - Volume
119,121 - Avg. Volume
867,723 - Market Cap (intraday)
2.012B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.03 - Earnings Date Mar 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
47.00
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
metsera.comRecent News: MTSR
View MorePerformance Overview: MTSR
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MTSR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MTSR
View MoreValuation Measures
Market Cap
1.91B
Enterprise Value
2.11B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.09%
Return on Equity (ttm)
-108.40%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-209.13M
Diluted EPS (ttm)
-2.03
Balance Sheet and Cash Flow
Total Cash (mrq)
352.45M
Total Debt/Equity (mrq)
3.41%
Levered Free Cash Flow (ttm)
-48.76M